08-10-2011, 09:31 AM
Approximately 10% of the patients with familial amyotrophic lateral sclerosis have an autosomal dominant mutation in copper/zinc superoxide dismutase gene SOD1. one therapy unde investigation for treatment is hammerhead ribozyme. which of the following best describes the mechanism by which a hammerhead ribozyme would be expected to treat ALS?
A. Ribozyme mediated degradation of mutant SOD1 mRNA
B. Ribozyme mediated destruction of mutant SOD1 gene
C. Ribozyme mediated inhibition of mutant SOD1 splicing
D. Ribozyme mediated inhibition of translation of mutant SOD1 mRNA
E. Ribozyme mediated inhibition of transcription from mutated SOD1 gene
F. Ribozyme mediated targeting of mutant SOD1 protein for destruction by the proteosome
A. Ribozyme mediated degradation of mutant SOD1 mRNA
B. Ribozyme mediated destruction of mutant SOD1 gene
C. Ribozyme mediated inhibition of mutant SOD1 splicing
D. Ribozyme mediated inhibition of translation of mutant SOD1 mRNA
E. Ribozyme mediated inhibition of transcription from mutated SOD1 gene
F. Ribozyme mediated targeting of mutant SOD1 protein for destruction by the proteosome